<p>NewAmsterdam Pharma Company N.V.（NASDAQ:NAMS - 获取免费报告）在周五上涨了 10.1%，因为加拿大皇家银行将该股票的目标价从 38.00 美元上调至 39.00 美元。加拿大皇家银行目前对该股票给予 “跑赢大盘” 的评级。NewAmsterdam Pharma 的交易最高达到 25.09 美元，最后交易价格为 25.28 美元。在午盘交易中，约有 596,445 股成交，较 868,590 股的日均成交量下降了 31%。该股票此前收于 22.96 美元。</p>
<p>其他几位研究分析师最近也对该股票发布了报告。Needham &amp; Company LLC 在 6 月 12 日的报告中重申了 “买入” 评级，并设定了 40.00 美元的目标价。花旗集团在 6 月 17 日的研究报告中开始覆盖 NewAmsterdam Pharma 的股票，给予 “买入” 评级和 42.00 美元的目标价。Cantor Fitzgerald 在 6 月 4 日的研究报告中开始覆盖 NewAmsterdam Pharma 的股票，设定了 “增持” 评级和 42.00 美元的目标价。高盛集团在 7 月 17 日的研究报告中开始覆盖 NewAmsterdam Pharma 的股票，设定了 “中性” 评级和 27.00 美元的目标价。最后，Wall Street Zen 在 7 月 5 日的报告中将 NewAmsterdam Pharma 的评级从 “卖出” 上调至 “持有”。两位分析师对该股票给予 “持有” 评级，八位分析师给予 “买入” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 41.20 美元。</p>
<p>获取 <strong>NewAmsterdam Pharma</strong> 的提醒：</p>
<p><strong>查看我们关于 NAMS 的最新报告</strong></p>
<h2>内部买卖</h2>
<p>在其他新闻中，董事 James N. Topper 在 6 月 16 日的交易中购买了 8,584 股公司的股票。该股票的平均购买成本为每股 19.50 美元，总价值为 167,388.00 美元。完成购买后，该董事直接持有 3,022,153 股公司的股票，价值为 58,931,983.50 美元。这代表着他们持股比例增加了 0.28%。该购买在向证券交易委员会的备案中披露，相关信息可在 SEC 网站上找到。此外，首席运营官 Douglas F. Kling 在 6 月 16 日的交易中出售了 100,000 股公司的股票。该股票的平均售价为 19.29 美元，总交易额为 1,929,000.00 美元。完成出售后，首席运营官持有 44,000 股公司的股票，价值为 848,760 美元。这笔交易代表着他们持股比例减少了 69.44%。该出售的披露信息可以在此找到。在上个季度，内部人士购买了价值 236,839 美元的 12,364 股公司股票，并出售了价值 4,025,887 美元的 198,612 股股票。目前，内部人士持有 20.84% 的股票。</p>
<h2>机构投资者对 NewAmsterdam Pharma 的看法</h2>
<p>大型投资者最近调整了对该公司的持股。Deerfield Management Company L.P. Series C 在第四季度将其在 NewAmsterdam Pharma 的持股增加了 378.4%。Deerfield Management Company L.P. Series C 现在拥有 4,314,340 股公司的股票，价值为 110,879,000 美元，在此期间又购买了 3,412,590 股。Frazier Life Sciences Management L.P.在第四季度将其在 NewAmsterdam Pharma 的持股增加了 23.8%。Frazier Life Sciences Management L.P.现在拥有 15,916,418 股公司的股票，价值为 409,052,000 美元，在上个季度又购买了 3,061,224 股。Wellington Management Group LLP 在第四季度将其在 NewAmsterdam Pharma 的持股增加了 2,410.4%。Wellington Management Group LLP 现在拥有 2,315,123 股公司的股票，价值为 59,499,000 美元，在此期间又收购了 2,222,900 股。Capital International Investors 在第四季度收购了价值约 53,007,000 美元的 NewAmsterdam Pharma 新股份。最后，RA Capital Management L.P.在第一季度将其在 NewAmsterdam Pharma 的持股增加了 14.6%。RA Capital Management L.P.现在拥有 10,138,938 股公司的股票，价值为 207,544,000 美元，在此期间又购买了 1,293,938 股。对冲基金和其他机构投资者持有该公司 89.89% 的股票。</p>
<h2>NewAmsterdam Pharma 上涨 11.5%</h2>
<p>该公司的市值为 28.8 亿美元，市盈率为-15.61，贝塔值为-0.02。该股票的 50 日移动平均价格为 20.58 美元，200 日移动平均价格为 20.01 美元。</p>
<p>NewAmsterdam Pharma（NASDAQ:NAMS - 获取免费报告）在 8 月 6 日星期三最后发布了季度收益数据。该公司报告本季度每股收益为（0.15 美元），超出市场共识预期的（0.52 美元）0.37 美元。该公司的季度收入为 1915 万美元，而分析师预期为 144 万美元。NewAmsterdam Pharma 的股本回报率为负的 28.78%，净利润率为负的 259.07%。分析师预计 NewAmsterdam Pharma Company N.V.在当前年度的每股收益将为-1.75。</p>
<h2>NewAmsterdam Pharma 公司简介</h2>
<p>（获取免费报告）</p>
<p>NewAmsterdam Pharma Company N.V.是一家晚期生物制药公司，开发旨在改善代谢疾病患者护理的疗法。该公司正在开发 obicetrapib，这是一种口服低剂量的胆固醇酯转移蛋白（CETP）抑制剂，目前正在进行多项临床试验，作为单药治疗和与依泽替米贝联合治疗降低 LDL-C 以应对心血管疾病。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，而非 NewAmsterdam Pharma</li>
<li>投资股票有不同类型</li>
<li>为什么 Axon 的 16% 激增预示着公共安全科技的新纪元</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>DraftKings 发布创纪录的季度业绩，瞄准盈利</li>
<li>股票交易：相对强弱指数（RSI）及其用途</li>
<li>亚马逊对 IonQ 进行股权投资——有潜在的上涨空间吗？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 NewAmsterdam Pharma 吗？</h2>
<p>在考虑 NewAmsterdam Pharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 NewAmsterdam Pharma 并不在名单上。</p>
<p>虽然 NewAmsterdam Pharma 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

NAMS

<p>NewAmsterdam Pharma（纳斯达克代码：NAMS）股价上涨 10.1%，因加拿大皇家银行将其目标价从 38 美元上调至 39 美元，并维持 “跑赢大盘” 评级。该股票交易价格为 25.28 美元，交易量下降 31%。其他分析师也发布了积极评级，市场共识目标价为 41.20 美元。内部交易方面，一名董事购买了股票，而首席运营官则出售了大量股份。机构投资者持有该股票的 89.89%，公司报告的季度每股收益为（0.15 美元），超出预期</p>

<p>NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) rose 10.1% on Friday after Royal Bank Of Canada raised their price target on the stock from $38.00 to $39.00. Royal Bank Of Canada currently has an outperform rating on the stock. NewAmsterdam Pharma traded as high as $25.09 and last traded at $25.28. Approximately 596,445 shares traded hands during mid-day trading, a decline of 31% from the average daily volume of 868,590 shares. The stock had previously closed at $22.96.</p>
<div class="lb-trans"><p>NewAmsterdam Pharma Company N.V.（NASDAQ:NAMS - 获取免费报告）在周五上涨了 10.1%，因为加拿大皇家银行将该股票的目标价从 38.00 美元上调至 39.00 美元。加拿大皇家银行目前对该股票给予 “跑赢大盘” 的评级。NewAmsterdam Pharma 的交易最高达到 25.09 美元，最后交易价格为 25.28 美元。在午盘交易中，约有 596,445 股成交，较 868,590 股的日均成交量下降了 31%。该股票此前收于 22.96 美元。</p>
</div><p>Several other research analysts also recently issued reports on the stock. Needham &amp; Company LLC restated a &#34;buy&#34; rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. Citigroup began coverage on shares of NewAmsterdam Pharma in a research note on Tuesday, June 17th. They issued a &#34;buy&#34; rating and a $42.00 price objective on the stock. Cantor Fitzgerald began coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, June 4th. They set an &#34;overweight&#34; rating and a $42.00 target price on the stock. The Goldman Sachs Group began coverage on shares of NewAmsterdam Pharma in a research report on Thursday, July 17th. They set a &#34;neutral&#34; rating and a $27.00 target price for the company. Finally, Wall Street Zen raised shares of NewAmsterdam Pharma from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, July 5th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $41.20.</p>
<div class="lb-trans"><p>其他几位研究分析师最近也对该股票发布了报告。Needham &amp; Company LLC 在 6 月 12 日的报告中重申了 “买入” 评级，并设定了 40.00 美元的目标价。花旗集团在 6 月 17 日的研究报告中开始覆盖 NewAmsterdam Pharma 的股票，给予 “买入” 评级和 42.00 美元的目标价。Cantor Fitzgerald 在 6 月 4 日的研究报告中开始覆盖 NewAmsterdam Pharma 的股票，设定了 “增持” 评级和 42.00 美元的目标价。高盛集团在 7 月 17 日的研究报告中开始覆盖 NewAmsterdam Pharma 的股票，设定了 “中性” 评级和 27.00 美元的目标价。最后，Wall Street Zen 在 7 月 5 日的报告中将 NewAmsterdam Pharma 的评级从 “卖出” 上调至 “持有”。两位分析师对该股票给予 “持有” 评级，八位分析师给予 “买入” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 41.20 美元。</p>
</div><p>Get <strong>NewAmsterdam Pharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>NewAmsterdam Pharma</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Report on NAMS</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 NAMS 的最新报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, Director James N. Topper acquired 8,584 shares of the company's stock in a transaction on Monday, June 16th. The stock was bought at an average cost of $19.50 per share, with a total value of $167,388.00. Following the completion of the purchase, the director directly owned 3,022,153 shares of the company's stock, valued at $58,931,983.50. This represents a 0.28% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, COO Douglas F. Kling sold 100,000 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $19.29, for a total transaction of $1,929,000.00. Following the completion of the sale, the chief operating officer owned 44,000 shares of the company's stock, valued at $848,760. This trade represents a 69.44% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders bought 12,364 shares of company stock valued at $236,839 and sold 198,612 shares valued at $4,025,887. 20.84% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 James N. Topper 在 6 月 16 日的交易中购买了 8,584 股公司的股票。该股票的平均购买成本为每股 19.50 美元，总价值为 167,388.00 美元。完成购买后，该董事直接持有 3,022,153 股公司的股票，价值为 58,931,983.50 美元。这代表着他们持股比例增加了 0.28%。该购买在向证券交易委员会的备案中披露，相关信息可在 SEC 网站上找到。此外，首席运营官 Douglas F. Kling 在 6 月 16 日的交易中出售了 100,000 股公司的股票。该股票的平均售价为 19.29 美元，总交易额为 1,929,000.00 美元。完成出售后，首席运营官持有 44,000 股公司的股票，价值为 848,760 美元。这笔交易代表着他们持股比例减少了 69.44%。该出售的披露信息可以在此找到。在上个季度，内部人士购买了价值 236,839 美元的 12,364 股公司股票，并出售了价值 4,025,887 美元的 198,612 股股票。目前，内部人士持有 20.84% 的股票。</p>
</div><h2>Institutional Investors Weigh In On NewAmsterdam Pharma</h2>
<div class="lb-trans"><h2>机构投资者对 NewAmsterdam Pharma 的看法</h2>
</div><p>Large investors have recently modified their holdings of the business. Deerfield Management Company L.P. Series C increased its stake in NewAmsterdam Pharma by 378.4% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company's stock worth $110,879,000 after buying an additional 3,412,590 shares during the period. Frazier Life Sciences Management L.P. raised its holdings in shares of NewAmsterdam Pharma by 23.8% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company's stock valued at $409,052,000 after buying an additional 3,061,224 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of NewAmsterdam Pharma by 2,410.4% in the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock worth $59,499,000 after acquiring an additional 2,222,900 shares during the period. Capital International Investors acquired a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at approximately $53,007,000. Finally, RA Capital Management L.P. grew its stake in shares of NewAmsterdam Pharma by 14.6% during the 1st quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company's stock worth $207,544,000 after purchasing an additional 1,293,938 shares during the period. Hedge funds and other institutional investors own 89.89% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该公司的持股。Deerfield Management Company L.P. Series C 在第四季度将其在 NewAmsterdam Pharma 的持股增加了 378.4%。Deerfield Management Company L.P. Series C 现在拥有 4,314,340 股公司的股票，价值为 110,879,000 美元，在此期间又购买了 3,412,590 股。Frazier Life Sciences Management L.P.在第四季度将其在 NewAmsterdam Pharma 的持股增加了 23.8%。Frazier Life Sciences Management L.P.现在拥有 15,916,418 股公司的股票，价值为 409,052,000 美元，在上个季度又购买了 3,061,224 股。Wellington Management Group LLP 在第四季度将其在 NewAmsterdam Pharma 的持股增加了 2,410.4%。Wellington Management Group LLP 现在拥有 2,315,123 股公司的股票，价值为 59,499,000 美元，在此期间又收购了 2,222,900 股。Capital International Investors 在第四季度收购了价值约 53,007,000 美元的 NewAmsterdam Pharma 新股份。最后，RA Capital Management L.P.在第一季度将其在 NewAmsterdam Pharma 的持股增加了 14.6%。RA Capital Management L.P.现在拥有 10,138,938 股公司的股票，价值为 207,544,000 美元，在此期间又购买了 1,293,938 股。对冲基金和其他机构投资者持有该公司 89.89% 的股票。</p>
</div><h2>NewAmsterdam Pharma Trading Up 11.5%</h2>
<div class="lb-trans"><h2>NewAmsterdam Pharma 上涨 11.5%</h2>
</div><p>The firm has a market capitalization of $2.88 billion, a PE ratio of -15.61 and a beta of -0.02. The stock's 50 day moving average price is $20.58 and its two-hundred day moving average price is $20.01.</p>
<div class="lb-trans"><p>该公司的市值为 28.8 亿美元，市盈率为-15.61，贝塔值为-0.02。该股票的 50 日移动平均价格为 20.58 美元，200 日移动平均价格为 20.01 美元。</p>
</div><p>NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.37. The company had revenue of $19.15 million for the quarter, compared to analyst estimates of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 28.78% and a negative net margin of 259.07%. Analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.</p>
<div class="lb-trans"><p>NewAmsterdam Pharma（NASDAQ:NAMS - 获取免费报告）在 8 月 6 日星期三最后发布了季度收益数据。该公司报告本季度每股收益为（0.15 美元），超出市场共识预期的（0.52 美元）0.37 美元。该公司的季度收入为 1915 万美元，而分析师预期为 144 万美元。NewAmsterdam Pharma 的股本回报率为负的 28.78%，净利润率为负的 259.07%。分析师预计 NewAmsterdam Pharma Company N.V.在当前年度的每股收益将为-1.75。</p>
</div><h2>NewAmsterdam Pharma Company Profile</h2>
<div class="lb-trans"><h2>NewAmsterdam Pharma 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.</p>
<div class="lb-trans"><p>NewAmsterdam Pharma Company N.V.是一家晚期生物制药公司，开发旨在改善代谢疾病患者护理的疗法。该公司正在开发 obicetrapib，这是一种口服低剂量的胆固醇酯转移蛋白（CETP）抑制剂，目前正在进行多项临床试验，作为单药治疗和与依泽替米贝联合治疗降低 LDL-C 以应对心血管疾病。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than NewAmsterdam Pharma</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Why Axon's 16% Surge Signals a New Era in Public Safety Tech</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>DraftKings Posts Record Quarter, Eyes Profitability</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>Amazon Takes an Equity Stake in IonQ—Any Upside Potential?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 NewAmsterdam Pharma</li>
<li>投资股票有不同类型</li>
<li>为什么 Axon 的 16% 激增预示着公共安全科技的新纪元</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>DraftKings 发布创纪录的季度业绩，瞄准盈利</li>
<li>股票交易：相对强弱指数（RSI）及其用途</li>
<li>亚马逊对 IonQ 进行股权投资——有潜在的上涨空间吗？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in NewAmsterdam Pharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 NewAmsterdam Pharma 吗？</h2>
</div><p>Before you consider NewAmsterdam Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 NewAmsterdam Pharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 NewAmsterdam Pharma 并不在名单上。</p>
</div><p>While NewAmsterdam Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 NewAmsterdam Pharma 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

NewAmsterdam Pharma（NASDAQ:NAMS）在分析师上调评级后股价上涨 10.1%